HC Wainwright reissued their buy rating on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Free Report) in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.
Armata Pharmaceuticals Stock Up 22.2 %
ARMP opened at $2.75 on Tuesday. Armata Pharmaceuticals has a 1 year low of $1.93 and a 1 year high of $4.48. The firm has a market capitalization of $99.50 million, a P/E ratio of -1.08 and a beta of 0.80.
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.13). As a group, equities research analysts forecast that Armata Pharmaceuticals will post -1.02 earnings per share for the current fiscal year.
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
See Also
- Five stocks we like better than Armata Pharmaceuticals
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Canada Bond Market Holiday: How to Invest and Trade
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
